Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. blood supply
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Blood Supply Articles & Analysis

24 news found

MedSource Labs Celebrates Black History Month

MedSource Labs Celebrates Black History Month

Last year, during Black History Month, our team at MedSource Labs took a closer look at the world of medical illustration and the ongoing efforts to address the lack of diversity in the field. We were inspired by the work of medical illustrators who are breaking barriers and ensuring that healthcare visuals represent the full spectrum of patients they serve. To see video, please click here What ...

ByMedsource Labs


LifeScan’s Response to the Invasion of Ukraine

LifeScan’s Response to the Invasion of Ukraine

Therefore, we are responding to the urgent humanitarian need for diabetes health medical supplies resulting from the invasion of Ukraine. As part of our longstanding commitment to supporting numerous relief efforts around the world, LifeScan is working with the non-profit humanitarian organization, Direct Relief, to respond to the urgent need to supply ...

ByLifeScan


An Easy, Predictable, and Simpler Way to Embolize Tumors

An Easy, Predictable, and Simpler Way to Embolize Tumors

Sawhney’s newest hydrogel company, Instylla Inc., founded in 2017, is addressing interventional oncology with a hydrogel-based liquid for tumor embolization, a therapy that shrinks tumors by blocking their blood supply. Instylla also has a side gig in hemorrhage control, a second early market for its technology. ...

ByInstylla, Inc.


Creative Medical Technology Announces Positive Top-Line Results for StemSpine Pilot Study

Creative Medical Technology Announces Positive Top-Line Results for StemSpine Pilot Study

"To our knowledge, this pilot is the first demonstration of the clinical efficacy of injecting bone marrow aspirate in areas surrounding the disc, thereby repairing, remodeling and improving the blood supply around the disc and lower back area. We believe StemSpine® represents an attractive non-surgical option for many of the millions of Americans who suffer ...

ByCreative Medical Technology Holdings, Inc. (CELZ)


Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine Study

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine Study

"To our knowledge, this is the first demonstration of the clinical efficacy of injecting bone marrow aspirate into areas surrounding the disc, which may repair, remodel and improve the blood supply around the disc and lower back area. We believe StemSpine® represents an attractive non-surgical option for many of the millions of Americans who suffer from ...

ByCreative Medical Technology Holdings, Inc. (CELZ)


ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors

ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors

Hypervascular tumors occur in both benign and malignant states and are characterized by blood supply from an abnormally large number of blood vessels. Microspheres embolization reduces or eliminates the blood flow to these tumors and is an effective interventional radiology therapy for treating this disease state. ...

ByABK Biomedical Inc.


Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

In AF, the upper chambers (atria) of the heart contract irregularly.5 As a result, the atria do not empty completely, and blood does not flow properly, potentially allowing blood clots to form. These blood clots can break loose and travel to the brain, resulting in a stroke.6 About Stroke Stroke is the second most common cause of death ...

ByBayer AG


Do You Know The Difference Between SHR And IPL

Do You Know The Difference Between SHR And IPL

SHR differs from traditional Laser/IPL it also targets the hair stem cells and blood supply that feeds it. It does not rely solely on the colour (pigment) of the hair to effectively destroy the targeted hair follicle. ...

ByBvlaser Bestview Medical and Beauty Equipment Co., Ltd


£1.1 million project to develop new biodegradable stents

£1.1 million project to develop new biodegradable stents

Severe peripheral vascular disease (PVD) is caused by the formation of blockages in arteries, which reduces blood supply to the brain, heart, kidneys and limbs causing strokes, heart attacks, kidney failure and limb amputations. ...

ByArterius Limited


XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT

XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT

This investigational gene therapy is designed to activate naturally occurring biological pathways by creating new vessels to improve blood flow to areas of the heart not receiving adequate blood supply. This restored blood supply could potentially improve patients’ quality of life by enabling them to resume ...

ByXyloCor Therapeutics


`Bilirubin` to eliminate inflammation... Vilix, the world`s first pharmaceutical drug

`Bilirubin` to eliminate inflammation... Vilix, the world`s first pharmaceutical drug

Myocardial infarction occurs after the patient has undergone stenting. If the blocked blood vessel is pierced with a fine wire mesh, a large amount of blood is supplied to the stopped heart. ...

ByBilix Co., Ltd.


Instylla First-In-Human Clinical Trial Published Results Demonstrate Technical Success and Persistent Embolization Across All Patients

Instylla First-In-Human Clinical Trial Published Results Demonstrate Technical Success and Persistent Embolization Across All Patients

This prospective, single-arm multicenter study demonstrated that Embrace HES effectively embolized malignant and benign hypervascular tumors by blocking tumor blood supply with technical success and persistent embolization,[i] as noted in imaging follow-up at 30-days, in all eight patients treated on this study. ...

ByInstylla, Inc.


CELLVIE featured in Biocentury`s Emerging Company Profile

CELLVIE featured in Biocentury`s Emerging Company Profile

James McCully, a cellvie AG co-founder, developed the approach at Harvard Medical School to ameliorate ischemia-reperfusion injury, which is the tissue damage caused when the blood supply returns after a period of ischemia. "What Jim observed in conditions of ischemia and reperfusion, like a heart attack, is that the mitochondria within the cells get damaged due ...

Bycellvie Inc.


Instylla Announces Enrollment of Initial Patients in the Embrace™ Hydrogel Embolic System Global Randomized Multi-Center Clinical Trial

Instylla Announces Enrollment of Initial Patients in the Embrace™ Hydrogel Embolic System Global Randomized Multi-Center Clinical Trial

As demonstrated previously in the completed First-in-Human (FIH) study, Embrace HES was effective at embolizing malignant and benign hypervascular tumors by blocking tumor blood supply with complete technical success and persistent embolization[i] as noted in imaging follow up at 30-days. ...

ByInstylla, Inc.


Biomodex Teams Up with Physicians at Three of the World’s Top Medical Centers to Develop a Cutting-Edge Training Solution for Treatment of Ischemic Stroke

Biomodex Teams Up with Physicians at Three of the World’s Top Medical Centers to Develop a Cutting-Edge Training Solution for Treatment of Ischemic Stroke

This type of stroke is a medical emergency that occurs when a clot forms inside a vessel supplying blood to the brain, where aspiration and mechanical thrombectomy are common treatments. These procedures involve inserting a catheter into an artery in the arm or groin and moving it towards the blood clot under X-ray guidance. The clot may be ...

ByBIOMODEX


MagicTouch SCB Granted ‘Breakthrough Device Designation’ for the treatment of Small Coronary Artery Lesions.

MagicTouch SCB Granted ‘Breakthrough Device Designation’ for the treatment of Small Coronary Artery Lesions.

” Each of the three main arteries supplying blood to the cardiac musculature, branches into progressively smaller vessels that eventually penetrate the cardiac musculature. Occlusion of these small vessels (coronary microvascular disease) can diminish blood flow to the heart leading to chest pain or shortness of breath, as well as diffuse ...

ByConcept Medical Inc.


XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina

XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina

XC001 is an investigational novel gene therapy designed to activate naturally occurring biological pathways to improve blood flow to areas of the heart not receiving adequate blood supply. ...

ByXyloCor Therapeutics


Bilirubin, which eliminates inflammation... Bilix, the world`s first drug

Bilirubin, which eliminates inflammation... Bilix, the world`s first drug

In the case of myocardial infarction, it occurs after a patient undergoes a stent procedure. When the clogged blood vessels are pierced with a fine wire mesh, a large amount of blood is supplied to the stopped heart. ...

ByBilix Co., Ltd.


Howard Leonhardt and Alex Richardson of Second Heart Assist discuss regenerating hearts and novel medical devices

Howard Leonhardt and Alex Richardson of Second Heart Assist discuss regenerating hearts and novel medical devices

It doesn’t really get any respect and a lot of people believe the aorta is just a conduit for carrying blood and no big deal. Any conduit will work. We’re discovering as we spend time and understand an aorta and the function better, that it’s much more than just a conduit for blood. A healthy, compliant aorta that’s able to beat and ...

BySecond Heart Assist, Inc.


QXMedical Licenses Bioresorbable Embolic Technology from U of MN

QXMedical Licenses Bioresorbable Embolic Technology from U of MN

These materials do not permanently occlude blood vessels supplying healthy tissue and may allow for better restoration of artery integrity after embolization compared to permanent microspheres and gels. ...

ByQXMedical

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT